文献速递淋巴瘤

整合基线与诱导结束PET的高肿瘤负荷滤泡性淋巴瘤预后模型:一项LYSA/FIL研究

Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
PubMed 文献 · Blood · 2018-03-20

该研究基于三项前瞻性试验的159例高肿瘤负荷滤泡性淋巴瘤患者,构建结合基线TMTV与诱导结束PET的预后模型。中位随访64个月,高TMTV(>510 cm³)与阳性EOI PET均为进展的独立显著危险因素,二者组合将人群分为3个风险组,5年PFS分别为67%、33%和23%。

要点

  • 高TMTV(>510 cm³)与阳性EOI PET是进展的独立显著危险因素。
  • 无危险因素组5年PFS为67%,1个危险因素组为33%,2个危险因素组为23%。
  • 该模型可识别2年内早期治疗失败风险极高的患者亚组。

核心结论

  • 结合基线TMTV与EOI PET的模型增强了PET分期和疗效评估的预后价值,可识别进展风险极高及2年内早期治疗失败的患者亚组。

研究设计与样本

  • 研究纳入三项前瞻性试验(2项LYSA研究及1项FIL试验)的159例高肿瘤负荷滤泡性淋巴瘤患者,中位随访64个月。

主要发现

  • 高TMTV(>510 cm³)与阳性EOI PET为进展的独立显著危险因素。
  • 无危险因素组(n=102,64%)5年PFS为67%,1个危险因素组(n=44,27%)为33%(HR 2.9,95%CI 1.8-4.9),2个危险因素组(n=13,8%)为23%(HR 4.6,95%CI 2.3-9.2)。
  • 无危险因素组2年PFS为90%,1个危险因素组为61%(HR 4.8,95%CI 2.2-10.4),2个危险因素组为46%(HR 8.1,95%CI 3.1-21.3)。

关键数值与推荐

  • 高TMTV定义为>510 cm³。
  • 风险分组:无危险因素(n=102,64%)、1个危险因素(n=44,27%)、2个危险因素(n=13,8%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Both total metabolic tumor volume (TMTV), computed on baseline positron emission tomography (PET), and end of induction (EOI) PET are imaging biomarkers showing promise for early risk stratification in patients with high-tumor-burden follicular lymphoma. A model was built incorporating these 2 factors in 159 patients from three prospective trials: 2 Lymphoma Study Association (LYSA) studies and 1 Fondazione Italiana Linfomi (FIL) trial. Median follow up was 64 months. High TMTV (>510 cm3) and positive EOI PET were independent, significant risk factors for progression. Their combination stratified the population into 3 risk groups: patients with no risk factors (n = 102; 64%) had a 5-year progression-free survival (PFS) of 67% vs 33% (hazard ratio [HR], 2.9; 95% confidence interval [CI], 1.8-4.9) for patients with 1 risk factor (n = 44; 27%) and only 23% (HR, 4.6; 95% CI, 2.3-9.2) for patients with both risk factors (n = 13; 8%). 2-year PFS was respectively 90% vs 61% (HR, 4.8; 95% CI, 2.2-10.4) and 46% (HR, 8.1; 95%CI, 3.1-21.3). This model enhances the prognostic value of PET staging and response assessment, identifying a subset of patients with a very high risk of progression and early treatment failure at 2 years.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cottereau AS, Versari A, Luminari S, et al. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Blood. 2018. PMID: 29559480. doi:10.1182/blood-2017-11-816298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。